|
Post by selluwud on Feb 4, 2015 15:46:28 GMT
How about this great news that is driving the lift in PPS. (tongue in cheek) Strong sell to just sell. Woo Woo
ValuEngine upgrades ONCOSEC MEDICAL from STRONG SELL to SELL. BY Investars Analyst Actions - public — 7:06 AM ET 02/04/2015
On February 3, 2015 ValuEngine upgraded ONCOSEC MEDICAL ( ONCS ) from STRONG SELL to SELL.
|
|
|
Post by jeffsimon99 on Feb 9, 2015 0:44:53 GMT
Just noticed that Grant Zeng, CFA for Zacks Small Cap Biotechs just recently DROPPED COVERAGE on ONCS in January. scr.zacks.com/files/January-27-2015_ONCS_Zeng_v001_d25n4t.pdfVery strange though. About 2.5 months ago he did a full research report and raised his Price Target from $2.00 to $4.00. Now he DROPS coverage and shows a PT of $0.50. I emailed him (thru his colleague Jason Napadano) to ask why and "what do you know that I don't"? If he answers me with anything interesting, I will post here. Jeff
|
|
|
Post by JHam on Feb 9, 2015 6:48:40 GMT
Just noticed that Grant Zeng, CFA for Zacks Small Cap Biotechs just recently DROPPED COVERAGE on ONCS in January. scr.zacks.com/files/January-27-2015_ONCS_Zeng_v001_d25n4t.pdfVery strange though. About 2.5 months ago he did a full research report and raised his Price Target from $2.00 to $4.00. Now he DROPS coverage and shows a PT of $0.50. I emailed him (thru his colleague Jason Napadano) to ask why and "what do you know that I don't"? If he answers me with anything interesting, I will post here. Jeff Thanks for letting us know if you get a response. Not too alarming though, analysts dropping companies happens often. Would be curious to know if there is a good reason behind it though.
|
|
|
Post by RLC on Feb 18, 2015 16:06:43 GMT
Unloaded a little bit more on this recent collaboration news with Heat Biologics. This isn't news that will create sustainable value IMO. I'm guessing we'll be back to the mid .30's by next week without some more compelling news...
|
|
|
Post by JHam on Feb 18, 2015 16:20:59 GMT
Unloaded a little bit more on this recent collaboration news with Heat Biologics. This isn't news that will create sustainable value IMO. I'm guessing we'll be back to the mid .30's by next week without some more compelling news... Agreed.
|
|
|
Post by lcd on Feb 18, 2015 18:47:47 GMT
RLC, I did the same and have another sell order sitting at .40 waiting for a buyer. This might be the start to a string of activity for ONCS but I am hedging my bets and taking a small lose to lower my total share count here.
|
|
|
Post by RLC on Feb 18, 2015 19:24:44 GMT
RLC, I did the same and have another sell order sitting at .40 waiting for a buyer. This might be the start to a string of activity for ONCS but I am hedging my bets and taking a small lose to lower my total share count here. I still maintain a small position and am looking to increase it when more clarity comes out regarding their combo trial with Keytruda. Until then, I agree with hedging your bet here as there's just a little bit too much uncertainty. My gut feeling is still telling me we'll see some exciting developments out of ONCS in the later part of this year.
|
|
|
Post by JHam on Feb 26, 2015 7:44:15 GMT
Off topic, but I won't be posting at the ONCS Google board anymore. It was getting completely out of control. Some members telling other members that they we're going to find them and kick their ass. One member even posting private information about where to come meet him (verified it on Twitter, turns out he was an MMA fighter too), which in turn caused the other member to call the cops and report him and the board itself. That kind of crap coupled with a total unbalanced viewpoint full of several narrow-minded lottery ticket mentality shareholders who do not permit any contrarian view was enough for me. I knew after they threw J&E under the bus, that my days were numbered there. So I unsubscribed.
|
|
|
Post by happyjawa on Feb 26, 2015 8:08:17 GMT
Off topic, but I won't be posting at the ONCS Google board anymore. It was getting completely out of control. Some members telling other members that they we're going to find them and kick their ass. One member even posting private information about where to come meet him (verified it on Twitter, turns out he was an MMA fighter too), which in turned caused the other member to call the cops and report him and the board itself. That kind of crap coupled with a total unbalanced viewpoint full of several narrow-minded lottery ticket mentality shareholders who do not permit any contrarian view was enough for me. I knew after they through J&E under the bus, that my days were numbered there. So I unsubscribed. Stuff has gotten crazy. After reading that board, I want to sell my position and be away from people for a while. On the bright side, I've stopped caring about daily movements and decided to place my attentions for the time being outside of the market, so at least some good has come from that board.
|
|
|
Post by JHam on Feb 26, 2015 9:33:31 GMT
Off topic, but I won't be posting at the ONCS Google board anymore. It was getting completely out of control. Some members telling other members that they we're going to find them and kick their ass. One member even posting private information about where to come meet him (verified it on Twitter, turns out he was an MMA fighter too), which in turned caused the other member to call the cops and report him and the board itself. That kind of crap coupled with a total unbalanced viewpoint full of several narrow-minded lottery ticket mentality shareholders who do not permit any contrarian view was enough for me. I knew after they through J&E under the bus, that my days were numbered there. So I unsubscribed. Stuff has gotten crazy. After reading that board, I want to sell my position and be away from people for a while. On the bright side, I've stopped caring about daily movements and decided to place my attentions for the time being outside of the market, so at least some good has come from that board. LOL, I know right. It made me want to move into the woods for the rest of my life and separate myself from the rest of the human race. Glad you got some benefit from it.
|
|
|
Post by RLC on Feb 26, 2015 13:37:44 GMT
Off topic, but I won't be posting at the ONCS Google board anymore. It was getting completely out of control. Some members telling other members that they we're going to find them and kick their ass. One member even posting private information about where to come meet him (verified it on Twitter, turns out he was an MMA fighter too), which in turn caused the other member to call the cops and report him and the board itself. That kind of crap coupled with a total unbalanced viewpoint full of several narrow-minded lottery ticket mentality shareholders who do not permit any contrarian view was enough for me. I knew after they threw J&E under the bus, that my days were numbered there. So I unsubscribed. This doesn't surprise me at all. I hadn't checked that forum in weeks, mainly because I've lessened my position significantly, but also because it was clear most of the people on that board were nuttier than a squirrel turd. I wish the few valuable contributors there would just take their posting over here.
|
|
|
Post by JHam on Feb 26, 2015 13:45:41 GMT
Off topic, but I won't be posting at the ONCS Google board anymore. It was getting completely out of control. Some members telling other members that they we're going to find them and kick their ass. One member even posting private information about where to come meet him (verified it on Twitter, turns out he was an MMA fighter too), which in turn caused the other member to call the cops and report him and the board itself. That kind of crap coupled with a total unbalanced viewpoint full of several narrow-minded lottery ticket mentality shareholders who do not permit any contrarian view was enough for me. I knew after they threw J&E under the bus, that my days were numbered there. So I unsubscribed. This doesn't surprise me at all. I hadn't checked that forum in weeks, mainly because I've lessened my position significantly, but also because it was clear most of the people on that board were nuttier than a squirrel turd. I wish the few valuable contributors there would just take their posting over here. LOL!!! Just wrote that down in my one-liner memory bank. Can't wait to use it, thanks!
|
|
|
Post by lcd on Feb 26, 2015 14:35:17 GMT
I only occasionally read that board but now I have to go spend a few minutes reading the craziness. I agree with others that the posters on that board alone make me regret holding any ONCS shares. I wonder if any of them also belong to icell?
|
|
|
Post by JHam on Feb 26, 2015 15:20:18 GMT
I only occasionally read that board but now I have to go spend a few minutes reading the craziness. I agree with others that the posters on that board alone make me regret holding any ONCS shares. I wonder if any of them also belong to icell? I think they now deleted most of the bad posts since they were worried the cops were going to get involved. Of course I took screenshots of the the whole thing (habit from post-iCell fiasco).
|
|
|
Post by happyjawa on Feb 26, 2015 19:23:32 GMT
I only occasionally read that board but now I have to go spend a few minutes reading the craziness. I agree with others that the posters on that board alone make me regret holding any ONCS shares. I wonder if any of them also belong to icell? I think they now deleted most of the bad posts since they were worried the cops were going to get involved. Of course I took screenshots of the the whole thing (habit from post-iCell fiasco). Market's aren't rational. I guess one only needs to read stock forums to realize that.
|
|
|
Post by JHam on Mar 3, 2015 20:39:17 GMT
Was tired of the misinformation being posted at the ONCS Google Board, so I emailed Dhillon myself. In particular, Furbush has been posting about how the IND should have been approved by the FDA by now and that we should hear about it soon. I was pretty confident that that was incorrect as ONCS wouldn't need to file a new IND for Immunopulse/IL-12. Here is my email followed by the response from Dhillon:
Mr. Dhillon,
Pleasure to meet you via email. I am a private investor in ONCS and I had a few questions that I was hoping you could shed some light on.
a) Do separate INDs need to be filed for the P2b combination, H&N, and triple negative breast trials?
b) If so, where are we in terms of the process concerning the P2b IND? Has it been submitted? Are we still waiting to hear back from the FDA? Have they given approval to begin the trial? Have they placed the trial on clinical hold while they seek more information on the trial?
c) If not, what is holding up this trial from commencing? Between the Stifel conference and corporate slide decks, it seems like we have been guided that enrollment will begin in either in early January or by the end of Q1. Still waiting to see it listed in clinicaltrials.gov. Will this trial start enrollment by the end of Q1?
d) How many patients do you plan on enrolling in the P2b combination trial?
e) At the Stifel conference you said that you hope to enter a registration trial by the end of 2016. And in order to do that, you would need to have the data from the extension trial. Does this mean that you plan on initiating and completing (top-line data) a P3 combination trial prior to the registration trial (end of 2016)? Or will the completion of the P2b trial take us to the registration trial without a P3 (unlikely correct?)?
Apologies for all of the questions and I appreciate your time. Looking forward to your response.
JHam
---
Hi JHam:
Thanks for your email. I’m in an all day meeting today. These are straight forward questions, but if it helps, email me back if you would like me to elaborate so I can give you a more detailed response.
A. No, all the new trials reference our existing pIL-12 IND. C. Everything is on schedule and we are looking forward to opening the upcoming clinical trials for enrollment. Please contact investors@oncosec.com if you have any further questions. D. Not yet disclosed E. The planned Phase IIb combination trial with KEYTRUDA will be statistically powered, and if we have a positive outcome on clinical response, it will allow OncoSec to potentially move forward with a Phase III registration trial.
Best,
Punit
|
|
|
Post by RLC on Mar 3, 2015 20:49:11 GMT
Was tired of the misinformation being posted at the ONCS Google Board, so I emailed Dhillon myself. In particular, Furbush has been posting about how the IND should have been approved by the FDA by now and that we should hear about it soon. I was pretty confident that that was incorrect as ONCS wouldn't need to file a new IND for Immunopulse/IL-12. Here is my email followed by the response from Dhillon: Mr. Dhillon, Pleasure to meet you via email. I am a private investor in ONCS and I had a few questions that I was hoping you could shed some light on. a) Do separate INDs need to be filed for the P2b combination, H&N, and triple negative breast trials? b) If so, where are we in terms of the process concerning the P2b IND? Has it been submitted? Are we still waiting to hear back from the FDA? Have they given approval to begin the trial? Have they placed the trial on clinical hold while they seek more information on the trial? c) If not, what is holding up this trial from commencing? Between the Stifel conference and corporate slide decks, it seems like we have been guided that enrollment will begin in either in early January or by the end of Q1. Still waiting to see it listed in clinicaltrials.gov. Will this trial start enrollment by the end of Q1? d) How many patients do you plan on enrolling in the P2b combination trial? e) At the Stifel conference you said that you hope to enter a registration trial by the end of 2016. And in order to do that, you would need to have the data from the extension trial. Does this mean that you plan on initiating and completing (top-line data) a P3 combination trial prior to the registration trial (end of 2016)? Or will the completion of the P2b trial take us to the registration trial without a P3 (unlikely correct?)? Apologies for all of the questions and I appreciate your time. Looking forward to your response. JHam --- Hi JHam: Thanks for your email. I’m in an all day meeting today. These are straight forward questions, but if it helps, email me back if you would like me to elaborate so I can give you a more detailed response. A. No, all the new trials reference our existing pIL-12 IND. C. Everything is on schedule and we are looking forward to opening the upcoming clinical trials for enrollment. Please contact investors@oncosec.com if you have any further questions. D. Not yet disclosed E. The planned Phase IIb combination trial with KEYTRUDA will be statistically powered, and if we have a positive outcome on clinical response, it will allow OncoSec to potentially move forward with a Phase III registration trial.Best, Punit Damn you're awesome! Love his answer to your last question.
|
|
|
Post by JHam on Mar 3, 2015 21:07:32 GMT
Just to save some time, here is what I just posted on Yahoo:
Furbush made a long post about how we were waiting for the FDA to approve or deny an IND for the P2b trial. I knew that this was not accurate, but just to make sure, I emailed Dhillon. His response was that ONCS does not need to file any new INDs for any of the new trials because "all the new trials reference our existing pIL-12 IND." Therefore there is no waiting for FDA approval for a new IND. I wanted to bring this up because many seem to be accepting this incorrect information as fact.
The information surrounding he future P3 and registration trial has been cloudy at best. Would there be a P3 trial, followed by a registration trial? No P3 trial? Etc...Well here is the answer. It looks like P3 and the registration trial will be the same: If the combination trial produces positive results, it "will allow OncoSec to potentially move forward with a Phase III registration trial."
This makes much more sense given the timeline stated at the Stifel Conference. I was also told that everything was on schedule for trial enrollment.
|
|
|
Post by JHam on Mar 3, 2015 21:11:44 GMT
Was tired of the misinformation being posted at the ONCS Google Board, so I emailed Dhillon myself. In particular, Furbush has been posting about how the IND should have been approved by the FDA by now and that we should hear about it soon. I was pretty confident that that was incorrect as ONCS wouldn't need to file a new IND for Immunopulse/IL-12. Here is my email followed by the response from Dhillon: Mr. Dhillon, Pleasure to meet you via email. I am a private investor in ONCS and I had a few questions that I was hoping you could shed some light on. a) Do separate INDs need to be filed for the P2b combination, H&N, and triple negative breast trials? b) If so, where are we in terms of the process concerning the P2b IND? Has it been submitted? Are we still waiting to hear back from the FDA? Have they given approval to begin the trial? Have they placed the trial on clinical hold while they seek more information on the trial? c) If not, what is holding up this trial from commencing? Between the Stifel conference and corporate slide decks, it seems like we have been guided that enrollment will begin in either in early January or by the end of Q1. Still waiting to see it listed in clinicaltrials.gov. Will this trial start enrollment by the end of Q1? d) How many patients do you plan on enrolling in the P2b combination trial? e) At the Stifel conference you said that you hope to enter a registration trial by the end of 2016. And in order to do that, you would need to have the data from the extension trial. Does this mean that you plan on initiating and completing (top-line data) a P3 combination trial prior to the registration trial (end of 2016)? Or will the completion of the P2b trial take us to the registration trial without a P3 (unlikely correct?)? Apologies for all of the questions and I appreciate your time. Looking forward to your response. JHam --- Hi JHam: Thanks for your email. I’m in an all day meeting today. These are straight forward questions, but if it helps, email me back if you would like me to elaborate so I can give you a more detailed response. A. No, all the new trials reference our existing pIL-12 IND. C. Everything is on schedule and we are looking forward to opening the upcoming clinical trials for enrollment. Please contact investors@oncosec.com if you have any further questions. D. Not yet disclosed E. The planned Phase IIb combination trial with KEYTRUDA will be statistically powered, and if we have a positive outcome on clinical response, it will allow OncoSec to potentially move forward with a Phase III registration trial.Best, Punit Damn you're awesome! Love his answer to your last question. Yeah that last bit gave me a lot of clarity. P3 and the registration trial are the same. That makes a lot more sense to me now, as I have been confused as to how they were going to start a registration trial by the end of 2016 if P2b isn't even finished by the end of 2015. P2b starts in 1Q, top-line data sometime next year, wait for the data in the extension trial toward the end of 2016, then go for the P3/registration trial. That makes a lot more sense to me and now I have a better idea of how I am going to play this.
|
|
|
Post by lcd on Mar 3, 2015 21:12:11 GMT
Thanks for sharing JHam. I find it odd to envision Dhillon sitting in a meeting emailing you, but I guess all day meetings are pretty boring no matter what your position is within an organization.
|
|